Cell Line Development Market Size, Share and Industry Analysis Report by Product, by Source, by Cell Line, by Application, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022

Description

List of Tables

The cell line development market is slated to grow considerably by 2028 on account of wide-scale production of vaccines around the world. In addition, the rapidly expanding biotechnology industry is likely to foster market development over the forecast period.

Recent technological innovation in cell line development has propelled market expansion. Moreover, extensive production of COVID-19 vaccines worldwide by leading pharmaceuticals and life sciences corporations has augmented industry uptake during the pandemic.

Furthermore, industry participants have been employing effective strategies to gain a competitive edge in the global market, thereby enhancing business dynamics. For instance, in February 2022, Cytiva, a leading pharmaceutical technology company, inked a partnership agreement with NecstGen, a non-profit contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to scale the development of cell and gene therapies.

The cell line development market has been segmented based on application, product, cell line, source, and region. From the product point of view, the market has further been bifurcated into accessories and consumables, reagents and media, and equipment. In 2021, the accessories and consumables sub-segment held a valuation of around USD 324 million and is foreseen to expand at a sturdy pace over the review timeline. This growth is attributed to growing R&D activities.

In terms of source, the cell line development market has been categorized into non-mammalian and mammalian. The mammalian sub-segment accounted for a staggering market share of about 72% in 2021 and is speculated to develop at a considerable growth rate through the projected period. Widespread production of monoclonal antibodies for targeted therapies is likely to accelerate segmental expansion.

From the cell line perspective, the market has been differentiated into primary cell lines, recombinant, continuous cell lines, and hybridomas. In 2021, the cell line development market size from the continuous cell lines sub-segment was valued at nearly USD 1.2 billion and is expected to witness optimistic progress over the analysis timeline. Prevalent adoption of continuous cell lines owing to their high effectiveness and low nutritional requirements is slated to bolster segmental growth over the following years.

With respect to application, the cell line development market has been segregated into research, bioproduction, tissue engineering, drug discovery, and toxicity testing. The toxicity testing sub-segment garnered approximately 21% market share in 2021 and is anticipated to reach a substantial revenue by the end of 2028 driven by the rise in drug development activities.

On the regional front, the Latin America cell line development industry is poised to expand at a CAGR of more than 10.2% through the study timeframe. Mounting incidences of cancer in the LATAM region is estimated to foster product outlook in the future.

Product Code: 429

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Cell line development industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 Source trends
- 2.1.4 Cell line trends
- 2.1.5 Application trends
- 2.1.6 Regional trends

Chapter 3 Cell Line Development Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Growing vaccine production worldwide
  - 3.3.1.2 Increasing prevalence of cancer across the globe
  - 3.3.1.3 Growth in biotechnology industry
  - 3.3.1.4 Innovations in biologics due to patent expiration
  - 3.3.1.5 Rising demand for monoclonal antibodies in developed economies
  - 3.3.1.6 Technological innovation in cell line development
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Complex regulatory landscape
  - 3.3.2.2 Issues related to stem cell research
3.4 Growth potential analysis
- 3.4.1 By product
- 3.4.2 By source
- 3.4.3 By cell line
- 3.4.4 By application
3.5 COVID-19 impact analysis
3.6 Porter's analysis
3.7 Competitive landscape, 2021
3.8 PESTEL analysis

Chapter 4 Cell Line Development Market, By Product

4.1 Key segment trends
4.2 Reagents and media
- 4.2.1 Reagents and media market, by region, 2017 - 2028 (USD Million)
4.3 Equipment
- 4.3.1 Equipment market, by region, 2017 - 2028 (USD Million)
- 4.3.2 Incubators
  - 4.3.2.1 Incubators market, by region, 2017 - 2028 (USD Million)
- 4.3.3 Centrifuges
  - 4.3.3.1 Centrifuges market, by region, 2017 - 2028 (USD Million)
- 4.3.4 Bioreactors
  - 4.3.4.1 Bioreactors market, by region, 2017 - 2028 (USD Million)
- 4.3.5 Storage equipment
  - 4.3.5.1 Storage equipment market, by region, 2017 - 2028 (USD Million)
- 4.3.6 Microscopes
  - 4.3.6.1 Microscopes market, by region, 2017 - 2028 (USD Million)
- 4.3.7 Electroporators
  - 4.3.7.1 Electroporates market, by region, 2017 - 2028 (USD Million)
- 4.3.8 Fluorescence-activated cell sorting (FACS)
  - 4.3.8.1 FACS market, by region, 2017 - 2028 (USD Million)
- 4.3.9 Others
  - 4.3.9.1 Others market, by region, 2017 - 2028 (USD Million)
4.4 Accessories and consumables
- 4.4.1 Accessories and consumables market, by region, 2017 - 2028 (USD Million)

Chapter 5 Cell Line Development Market, By Source

5.1 Key segment trends
5.2 Mammalian
- 5.2.1 Mammalian market, by region, 2017 - 2028 (USD Million)
5.3 Non-mammalian
- 5.3.1 Non-mammalian market, by region, 2017 - 2028 (USD Million)
- 5.3.2 Insects
  - 5.3.2.1 Insects market, by region, 2017 - 2028 (USD Million)
- 5.3.3 Amphibians
  - 5.3.3.1 Amphibians market, by region, 2017 - 2028 (USD Million)

Chapter 6 Cell Line Development Market, By Cell Line

6.1 Key segment trends
6.2 Recombinant
- 6.2.1 Recombinant cell lines market, by region, 2017 - 2028 (USD Million)
6.3 Hybridomas
- 6.3.1 Hybridomas cell lines market, by region, 2017 - 2028 (USD Million)
6.4 Continuous cell lines
- 6.4.1 Continuous cell lines market, by region, 2017 - 2028 (USD Million)
6.5 Primary cell lines
- 6.5.1 Primary cell lines market, by region, 2017 - 2028 (USD Million)

Chapter 7 Cell Line Development Market, By Application

7.1 Key segment trends
7.2 Bioproduction
- 7.2.1 Bioproduction market, by region, 2017 - 2028 (USD Million)
7.3 Drug discovery
- 7.3.1 Drug discovery market, by region, 2017 - 2028 (USD Million)
7.4 Toxicity testing
- 7.4.1 Toxicity testing market, by region, 2017 - 2028 (USD Million)
7.5 Tissue engineering
- 7.5.1 Tissue engineering market, by region, 2017 - 2028 (USD Million)
7.6 Research
- 7.6.1 Research market, by region, 2017 - 2028 (USD Million)

Chapter 8 Cell Line Development Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 Market size, by country 2017-2028
- 8.2.2 Market size, by product, 2017-2028
  - 8.2.2.1 Market size, by equipment, 2017-2028
- 8.2.3 Market size, by source, 2017-2028
  - 8.2.3.1 Market size, by non-mammalian, 2017-2028
- 8.2.4 Market size, by cell line, 2017-2028
- 8.2.5 Market size, by application, 2017-2028
- 8.2.6 U.S.
  - 8.2.6.1 Market size, by product, 2017-2028
    - 8.2.6.1.1 Market size, by equipment, 2017-2028
  - 8.2.6.2 Market size, by source, 2017-2028
    - 8.2.6.2.1 Market size, by non-mammalian, 2017-2028
  - 8.2.6.3 Market size, by cell line, 2017-2028
  - 8.2.6.4 Market size, by application, 2017-2028
- 8.2.7 Canada
  - 8.2.7.1 Market size, by product, 2017-2028
    - 8.2.7.1.1 Market size, by equipment, 2017-2028
  - 8.2.7.2 Market size, by source, 2017-2028
    - 8.2.7.2.1 Market size, by non-mammalian, 2017-2028
  - 8.2.7.3 Market size, by cell line, 2017-2028
  - 8.2.7.4 Market size, by application, 2017-2028
8.3 Europe
- 8.3.1 Market size, by country 2017-2028
- 8.3.2 Market size, by product, 2017-2028
  - 8.3.2.1 Market size, by equipment, 2017-2028
- 8.3.3 Market size, by source, 2017-2028
  - 8.3.3.1 Market size, by non-mammalian, 2017-2028
- 8.3.4 Market size, by cell line, 2017-2028
- 8.3.5 Market size, by application, 2017-2028
- 8.3.6 Germany
  - 8.3.6.1 Market size, by product, 2017-2028
    - 8.3.6.1.1 Market size, by equipment, 2017-2028
  - 8.3.6.2 Market size, by source, 2017-2028
    - 8.3.6.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.6.3 Market size, by cell line, 2017-2028
  - 8.3.6.4 Market size, by application, 2017-2028
- 8.3.7 France
  - 8.3.7.1 Market size, by product, 2017-2028
    - 8.3.7.1.1 Market size, by equipment, 2017-2028
  - 8.3.7.2 Market size, by source, 2017-2028
    - 8.3.7.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.7.3 Market size, by cell line, 2017-2028
  - 8.3.7.4 Market size, by application, 2017-2028
- 8.3.8 UK
  - 8.3.8.1 Market size, by product, 2017-2028
    - 8.3.8.1.1 Market size, by equipment, 2017-2028
  - 8.3.8.2 Market size, by source, 2017-2028
    - 8.3.8.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.8.3 Market size, by cell line, 2017-2028
  - 8.3.8.4 Market size, by application, 2017-2028
- 8.3.9 Spain
  - 8.3.9.1 Market size, by product, 2017-2028
    - 8.3.9.1.1 Market size, by equipment, 2017-2028
  - 8.3.9.2 Market size, by source, 2017-2028
    - 8.3.9.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.9.3 Market size, by cell line, 2017-2028
  - 8.3.9.4 Market size, by application, 2017-2028
- 8.3.10 Italy
  - 8.3.10.1 Market size, by product, 2017-2028
    - 8.3.10.1.1 Market size, by equipment, 2017-2028
  - 8.3.10.2 Market size, by source, 2017-2028
    - 8.3.10.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.10.3 Market size, by cell line, 2017-2028
  - 8.3.10.4 Market size, by application, 2017-2028
- 8.3.11 Russia
  - 8.3.11.1 Market size, by product, 2017-2028
    - 8.3.11.1.1 Market size, by equipment, 2017-2028
  - 8.3.11.2 Market size, by source, 2017-2028
    - 8.3.11.2.1 Market size, by non-mammalian, 2017-2028
  - 8.3.11.3 Market size, by cell line, 2017-2028
  - 8.3.11.4 Market size, by application, 2017-2028
8.4 Asia Pacific
- 8.4.1 Market size, by country 2017-2028
- 8.4.2 Market size, by product, 2017-2028
  - 8.4.2.1 Market size, by equipment, 2017-2028
- 8.4.3 Market size, by source, 2017-2028
  - 8.4.3.1 Market size, by non-mammalian, 2017-2028
- 8.4.4 Market size, by cell line, 2017-2028
- 8.4.5 Market size, by application, 2017-2028
- 8.4.6 Japan
  - 8.4.6.1 Market size, by product, 2017-2028
    - 8.4.6.1.1 Market size, by equipment, 2017-2028
  - 8.4.6.2 Market size, by source, 2017-2028
    - 8.4.6.2.1 Market size, by non-mammalian, 2017-2028
  - 8.4.6.3 Market size, by cell line, 2017-2028
  - 8.4.6.4 Market size, by application, 2017-2028
- 8.4.7 China
  - 8.4.7.1 Market size, by product, 2017-2028
    - 8.4.7.1.1 Market size, by equipment, 2017-2028
  - 8.4.7.2 Market size, by source, 2017-2028
    - 8.4.7.2.1 Market size, by non-mammalian, 2017-2028
  - 8.4.7.3 Market size, by cell line, 2017-2028
  - 8.4.7.4 Market size, by application, 2017-2028
- 8.4.8 India
  - 8.4.8.1 Market size, by product, 2017-2028
    - 8.4.8.1.1 Market size, by equipment, 2017-2028
  - 8.4.8.2 Market size, by source, 2017-2028
    - 8.4.8.2.1 Market size, by non-mammalian, 2017-2028
  - 8.4.8.3 Market size, by cell line, 2017-2028
  - 8.4.8.4 Market size, by application, 2017-2028
- 8.4.9 South Korea
  - 8.4.9.1 Market size, by product, 2017-2028
    - 8.4.9.1.1 Market size, by equipment, 2017-2028
  - 8.4.9.2 Market size, by source, 2017-2028
    - 8.4.9.2.1 Market size, by non-mammalian, 2017-2028
  - 8.4.9.3 Market size, by cell line, 2017-2028
  - 8.4.9.4 Market size, by application, 2017-2028
- 8.4.10 Australia
  - 8.4.10.1 Market size, by product, 2017-2028
    - 8.4.10.1.1 Market size, by equipment, 2017-2028
  - 8.4.10.2 Market size, by source, 2017-2028
    - 8.4.10.2.1 Market size, by non-mammalian, 2017-2028
  - 8.4.10.3 Market size, by cell line, 2017-2028
  - 8.4.10.4 Market size, by application, 2017-2028
8.5 Latin America
- 8.5.1 Market size, by country 2017-2028
- 8.5.2 Market size, by product, 2017-2028
  - 8.5.2.1 Market size, by equipment, 2017-2028
- 8.5.3 Market size, by source, 2017-2028
  - 8.5.3.1 Market size, by non-mammalian, 2017-2028
- 8.5.4 Market size, by cell line, 2017-2028
- 8.5.5 Market size, by application, 2017-2028
- 8.5.6 Mexico
  - 8.5.6.1 Market size, by product, 2017-2028
    - 8.5.6.1.1 Market size, by equipment, 2017-2028
  - 8.5.6.2 Market size, by source, 2017-2028
    - 8.5.6.2.1 Market size, by non-mammalian, 2017-2028
  - 8.5.6.3 Market size, by cell line, 2017-2028
  - 8.5.6.4 Market size, by application, 2017-2028
- 8.5.7 Brazil
  - 8.5.7.1 Market size, by product, 2017-2028
    - 8.5.7.1.1 Market size, by equipment, 2017-2028
  - 8.5.7.2 Market size, by source, 2017-2028
    - 8.5.7.2.1 Market size, by non-mammalian, 2017-2028
  - 8.5.7.3 Market size, by cell line, 2017-2028
  - 8.5.7.4 Market size, by application, 2017-2028
8.6 MEA
- 8.6.1 Market size, by country 2017-2028
- 8.6.2 Market size, by product, 2017-2028
  - 8.6.2.1 Market size, by equipment, 2017-2028
- 8.6.3 Market size, by source, 2017-2028
  - 8.6.3.1 Market size, by non-mammalian, 2017-2028
- 8.6.4 Market size, by cell line, 2017-2028
- 8.6.5 Market size, by application, 2017-2028
- 8.6.6 South Africa
  - 8.6.6.1 Market size, by product, 2017-2028
    - 8.6.6.1.1 Market size, by equipment, 2017-2028
  - 8.6.6.2 Market size, by source, 2017-2028
    - 8.6.6.2.1 Market size, by non-mammalian, 2017-2028
  - 8.6.6.3 Market size, by cell line, 2017-2028
  - 8.6.6.4 Market size, by application, 2017-2028
- 8.6.7 Saudi Arabia
  - 8.6.7.1 Market size, by product, 2017-2028
    - 8.6.7.1.1 Market size, by equipment, 2017-2028
  - 8.6.7.2 Market size, by source, 2017-2028
    - 8.6.7.2.1 Market size, by non-mammalian, 2017-2028
  - 8.6.7.3 Market size, by cell line, 2017-2028
  - 8.6.7.4 Market size, by application, 2017-2028

Chapter 9 Company Profiles

9.1 Strategy dashboard, 2021
9.2 Advanced Instruments, LLC
- 9.2.1 Business overview
- 9.2.2 Financial data
- 9.2.3 Product landscape
- 9.2.4 Strategic outlook
- 9.2.5 SWOT analysis
9.3 AGC Biologics
- 9.3.1 Business overview
- 9.3.2 Financial data
- 9.3.3 Product landscape
- 9.3.4 SWOT analysis
9.4 Catalent
- 9.4.1 Business overview
- 9.4.2 Financial data
- 9.4.3 Products landscape
- 9.4.4 Strategic outlook
- 9.4.5 SWOT analysis
9.5 Corning Inc.
- 9.5.1 Business overview
- 9.5.2 Financial data
- 9.5.3 Product landscape
- 9.5.4 Strategic outlook
- 9.5.5 SWOT analysis
9.6 Cyagen
- 9.6.1 Business overview
- 9.6.2 Financial data
- 9.6.3 Product landscape
- 9.6.4 SWOT analysis
9.7 Cytiva (Danaher Corporation)
- 9.7.1 Business overview
- 9.7.2 Financial information
- 9.7.3 Product landscape
- 9.7.4 Strategic outlook
- 9.7.5 SWOT analysis
9.8 Eurofins Scientific
- 9.8.1 Business Overview
- 9.8.2 Financial data
- 9.8.3 Product Landscape
- 9.8.4 Strategic outlook
- 9.8.5 SWOT analysis
9.9 Fujifilm Diosynth Biotechnologies
- 9.9.1 Business overview
- 9.9.2 Financial data
- 9.9.3 Product Landscape
- 9.9.4 Strategic outlook
- 9.9.5 SWOT analysis
9.10 Genscript Biotech
- 9.10.1 Business Overview
- 9.10.2 Financial data
- 9.10.3 Product landscape
- 9.10.4 SWOT analysis
9.11 Horizon Discovery
- 9.11.1 Business Overview
- 9.11.2 Financial data
- 9.11.3 Product Landscape
- 9.11.4 SWOT analysis
9.12 Imgenex
- 9.12.1 Business overview
- 9.12.2 Financial data
- 9.12.3 Service landscape
- 9.12.4 SWOT analysis
9.13 Lonza Group AG
- 9.13.1 Business Overview
- 9.13.2 Financial Data
- 9.13.3 Product Landscape
- 9.13.4 Strategic Outlook
- 9.13.5 SWOT analysis
9.14 NAEJA RGM Pharmaceuticals
- 9.14.1 Business Overview
- 9.14.2 Financial data
- 9.14.3 Product Landscape
- 9.14.4 SWOT analysis
9.15 Novartis
- 9.15.1 Business overview
- 9.15.2 Financial data
- 9.15.3 Product landscape
- 9.15.4 Strategic outlook
- 9.15.5 SWOT analysis
9.16 Premas Biotech
- 9.16.1 Business Overview
- 9.16.2 Financial data
- 9.16.3 Product Landscape
- 9.16.4 SWOT analysis
9.17 ProBioGen
- 9.17.1 Business overview
- 9.17.2 Financial data
- 9.17.3 Product landscape
- 9.17.4 SWOT analysis
9.18 Promocell
- 9.18.1 Business overview
- 9.18.2 Financial data
- 9.18.3 Product landscape
- 9.18.4 Strategic outlook
- 9.18.5 SWOT analysis
9.19 Rentschler Biopharma SE
- 9.19.1 Business overview
- 9.19.2 Financial data
- 9.19.3 Service landscape
- 9.19.4 SWOT analysis
9.20 Samsung Biologics
- 9.20.1 Business overview
- 9.20.2 Financial data
- 9.20.3 Products landscape
- 9.20.4 Strategic outlook
- 9.20.5 SWOT analysis
9.21 Sartorius AG
- 9.21.1 Business overview
- 9.21.2 Financial data
- 9.21.3 Product landscape
- 9.21.4 Strategic outlook
- 9.21.5 SWOT Analysis
9.22 Selexis SA
- 9.22.1 Business overview
- 9.22.2 Financial data
- 9.22.3 Product landscape
- 9.22.4 Strategic outlook
- 9.22.5 SWOT analysis
9.23 Sigma Aldrich (Merck KGaA)
- 9.23.1 Business overview
- 9.23.2 Financial data
- 9.23.3 Product landscape
- 9.23.4 Strategic Outlook
- 9.23.5 SWOT analysis
9.24 Syngene International Limited
- 9.24.1 Business overview
- 9.24.2 Financial data
- 9.24.3 Service landscape
- 9.24.4 SWOT analysis
9.25 Thermo Fisher Scientific
- 9.25.1 Business overview
- 9.25.2 Financial data
- 9.25.3 Product landscape
- 9.25.4 SWOT analysis
9.26 Vista Biologics
- 9.26.1 Business overview
- 9.26.2 Financial data
- 9.26.3 Product Landscape
- 9.26.4 SWOT analysis
9.27 WuXi AppTec
- 9.27.1 Business overview
- 9.27.2 Financial data
- 9.27.3 Service landscape
- 9.27.4 Strategic outlook
- 9.27.5 SWOT analysis